{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:39:53Z","timestamp":1789907993949,"version":"4.0.1"},"reference-count":28,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.3892\/mmr.2015.3562","type":"journal-article","created":{"date-parts":[[2015,3,28]],"date-time":"2015-03-28T21:44:05Z","timestamp":1427579045000},"page":"2211-2216","source":"Crossref","is-referenced-by-count":45,"title":["HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer"],"prefix":"10.3892","volume":"12","author":[{"given":"YU","family":"WANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HONGLI","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TIEFANG","family":"SONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YITING","family":"ZOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JING","family":"JIANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LEI","family":"FANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PEILING","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"key20180108022253_b1-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"key20180108022253_b2-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(05)17716-2","article-title":"Epidemiology of ovarian cancer: a status report","volume":"365","author":"Bertone-Johnson","year":"2005","journal-title":"Lancet"},{"key":"key20180108022253_b3-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"key20180108022253_b4-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/modpathol.3800306","article-title":"Origins and molecular pathology of ovarian cancer","volume":"18","author":"Bell","year":"2005","journal-title":"Mod Pathol"},{"key":"key20180108022253_b5-mmr-12-02-2211","first-page":"312","article-title":"Drug resistance in ovarian cancer: from the laboratory to the clinic","volume":"92","author":"Sood","year":"1998","journal-title":"Obstet Gynecol"},{"key":"key20180108022253_b6-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"key20180108022253_b7-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"e1000459","DOI":"10.1371\/journal.pgen.1000459","article-title":"The genetic signatures of noncoding RNAs","volume":"5","author":"Mattick","year":"2009","journal-title":"PLoS Genet"},{"key":"key20180108022253_b8-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0065-230X(07)99003-X","article-title":"The RNA continent","volume":"99","author":"Yasuda","year":"2008","journal-title":"Adv Cancer Res"},{"key":"key20180108022253_b9-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2009.02.006","article-title":"Evolution and functions of long noncoding RNAs","volume":"136","author":"Ponting","year":"2009","journal-title":"Cell"},{"key":"key20180108022253_b10-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"key20180108022253_b11-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1245\/s10434-011-1581-y","article-title":"Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepato-cellular carcinoma patients following liver transplantation","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"key20180108022253_b12-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-11-1021","article-title":"Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers","volume":"71","author":"Kogo","year":"2011","journal-title":"Cancer Res"},{"key":"key20180108022253_b13-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/onc.2012.193","article-title":"HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer","volume":"32","author":"Kim","year":"2013","journal-title":"Oncogene"},{"key":"key20180108022253_b14-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-13-464","article-title":"The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer","volume":"13","author":"Liu","year":"2013","journal-title":"BMC Cancer"},{"key":"key20180108022253_b15-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.cell.2007.05.022","article-title":"Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs","volume":"129","author":"Rinn","year":"2007","journal-title":"Cell"},{"key":"key20180108022253_b16-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108022253_b17-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","article-title":"High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis","volume":"89","author":"Godwin","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108022253_b18-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1126\/science.3175622","article-title":"Overexpression of metallothionein confers resistance to anticancer drugs","volume":"241","author":"Kelley","year":"1998","journal-title":"Science"},{"key":"key20180108022253_b19-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI115080","article-title":"Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation","volume":"87","author":"Parker","year":"1991","journal-title":"J Clin Invest"},{"key":"key20180108022253_b20-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00280-005-0148-7","article-title":"Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells","volume":"58","author":"Stordal","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108022253_b21-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nrc1232","article-title":"Applying the principles of stem-cell biology to cancer","volume":"3","author":"Pardal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key20180108022253_b22-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2741\/3693","article-title":"Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer","volume":"16","author":"Curley","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"key20180108022253_b23-mmr-12-02-2211","first-page":"444756","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"7","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"key20180108022253_b24-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbrc.2007.01.159","article-title":"Tumour-initiating cells vs. cancer \u2018stem\u2019 cells and CD133: what\u2019s in the name?","volume":"355","author":"Neuzil","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108022253_b25-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1128\/MCB.01432-06","article-title":"The polycomb group protein Suz12 is required for embryonic stem cell differentiation","volume":"27","author":"Pasini","year":"2007","journal-title":"Mol Cell Biol"},{"key":"key20180108022253_b26-mmr-12-02-2211","first-page":"364","article-title":"EZH2: a pivotal regulator for controlling cell differentiation","volume":"4","author":"Chen","year":"2012","journal-title":"Am J Transl Res"},{"key":"key20180108022253_b27-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"11667","DOI":"10.1073\/pnas.0904715106","article-title":"Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression","volume":"106","author":"Khalil","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108022253_b28-mmr-12-02-2211","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/stem.1547","article-title":"Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cells lines","volume":"31","author":"P\u00e1dua Alves","year":"2013","journal-title":"Stem Cells"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2015.3562\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T23:24:39Z","timestamp":1515367479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2015.3562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,3,27]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3892\/mmr.2015.3562"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2015.3562","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}